Cargando…

In vitro efficacy of Artemisia extracts against SARS-CoV-2

BACKGROUND: Traditional medicines based on herbal extracts have been proposed as affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Teas and drinks containing extracts of Artemisia annua and Ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Chuanxiong, Trimpert, Jakob, Moon, Sooyeon, Haag, Rainer, Gilmore, Kerry, Kaufer, Benedikt B., Seeberger, Peter H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424155/
https://www.ncbi.nlm.nih.gov/pubmed/34496903
http://dx.doi.org/10.1186/s12985-021-01651-8
_version_ 1783749615089090560
author Nie, Chuanxiong
Trimpert, Jakob
Moon, Sooyeon
Haag, Rainer
Gilmore, Kerry
Kaufer, Benedikt B.
Seeberger, Peter H.
author_facet Nie, Chuanxiong
Trimpert, Jakob
Moon, Sooyeon
Haag, Rainer
Gilmore, Kerry
Kaufer, Benedikt B.
Seeberger, Peter H.
author_sort Nie, Chuanxiong
collection PubMed
description BACKGROUND: Traditional medicines based on herbal extracts have been proposed as affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Teas and drinks containing extracts of Artemisia annua and Artemisia afra have been widely used in Africa in efforts to prevent SARS-CoV-2 infection and fight COVID-19. METHODS: The plant extracts and Covid-Organics drink produced in Madagascar were tested for plaque reduction using both feline coronavirus and SARS-CoV-2 in vitro. Their cytotoxicities were also investigated. RESULTS: Several extracts as well as Covid-Organics inhibited SARS-CoV-2 and FCoV infection at concentrations that did not affect cell viability. CONCLUSIONS: Some plant extracts show inhibitory activity against FCoV and SARS-CoV-2. However, it remains unclear whether peak plasma concentrations in humans can reach levels needed to inhibit viral infection following consumption of teas or Covid-Organics. Clinical studies are required to evaluate the utility of these drinks for COVID-19 prevention or treatment of patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-021-01651-8.
format Online
Article
Text
id pubmed-8424155
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84241552021-09-08 In vitro efficacy of Artemisia extracts against SARS-CoV-2 Nie, Chuanxiong Trimpert, Jakob Moon, Sooyeon Haag, Rainer Gilmore, Kerry Kaufer, Benedikt B. Seeberger, Peter H. Virol J Short Report BACKGROUND: Traditional medicines based on herbal extracts have been proposed as affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Teas and drinks containing extracts of Artemisia annua and Artemisia afra have been widely used in Africa in efforts to prevent SARS-CoV-2 infection and fight COVID-19. METHODS: The plant extracts and Covid-Organics drink produced in Madagascar were tested for plaque reduction using both feline coronavirus and SARS-CoV-2 in vitro. Their cytotoxicities were also investigated. RESULTS: Several extracts as well as Covid-Organics inhibited SARS-CoV-2 and FCoV infection at concentrations that did not affect cell viability. CONCLUSIONS: Some plant extracts show inhibitory activity against FCoV and SARS-CoV-2. However, it remains unclear whether peak plasma concentrations in humans can reach levels needed to inhibit viral infection following consumption of teas or Covid-Organics. Clinical studies are required to evaluate the utility of these drinks for COVID-19 prevention or treatment of patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-021-01651-8. BioMed Central 2021-09-08 /pmc/articles/PMC8424155/ /pubmed/34496903 http://dx.doi.org/10.1186/s12985-021-01651-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Short Report
Nie, Chuanxiong
Trimpert, Jakob
Moon, Sooyeon
Haag, Rainer
Gilmore, Kerry
Kaufer, Benedikt B.
Seeberger, Peter H.
In vitro efficacy of Artemisia extracts against SARS-CoV-2
title In vitro efficacy of Artemisia extracts against SARS-CoV-2
title_full In vitro efficacy of Artemisia extracts against SARS-CoV-2
title_fullStr In vitro efficacy of Artemisia extracts against SARS-CoV-2
title_full_unstemmed In vitro efficacy of Artemisia extracts against SARS-CoV-2
title_short In vitro efficacy of Artemisia extracts against SARS-CoV-2
title_sort in vitro efficacy of artemisia extracts against sars-cov-2
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424155/
https://www.ncbi.nlm.nih.gov/pubmed/34496903
http://dx.doi.org/10.1186/s12985-021-01651-8
work_keys_str_mv AT niechuanxiong invitroefficacyofartemisiaextractsagainstsarscov2
AT trimpertjakob invitroefficacyofartemisiaextractsagainstsarscov2
AT moonsooyeon invitroefficacyofartemisiaextractsagainstsarscov2
AT haagrainer invitroefficacyofartemisiaextractsagainstsarscov2
AT gilmorekerry invitroefficacyofartemisiaextractsagainstsarscov2
AT kauferbenediktb invitroefficacyofartemisiaextractsagainstsarscov2
AT seebergerpeterh invitroefficacyofartemisiaextractsagainstsarscov2